Goldman Sachs
ADCT icon

Goldman Sachs’s ADC Therapeutics ADCT Stock Holding History

Goldman Sachs’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Buy
1,653,026
+12,154
+0.7% +$47.9K ﹤0.01% 3485
2025
Q4 		$5.79M Buy
1,640,872
+46,438
+3% +$188K ﹤0.01% 3614
2025
Q3 		$6.38M Buy
1,594,434
+51,832
+3% +$163K ﹤0.01% 3426
2025
Q2 		$4.13M Sell
1,542,602
-40,510
-3% -$85.2K ﹤0.01% 3589
2025
Q1 		$2.23M Sell
1,583,112
-90,065
-5% -$153K ﹤0.01% 4066
2024
Q4 		$3.33M Sell
1,673,177
-15,417
-0.9% -$40.3K ﹤0.01% 3843
2024
Q3 		$5.32M Buy
1,688,594
+163,877
+11% +$517K ﹤0.01% 3290
2024
Q2 		$4.82M Sell
1,524,717
-15,792
-1% -$62.8K ﹤0.01% 3187
2024
Q1 		$6.92M Buy
1,540,509
+80,995
+6% +$299K ﹤0.01% 2809
2023
Q4 		$2.42M Buy
1,459,514
+406,536
+39% +$375K ﹤0.01% 3771
2023
Q3 		$945K Sell
1,052,978
-84,611
-7% -$113K ﹤0.01% 4307
2023
Q2 		$2.45M Sell
1,137,589
-1,216,116
-52% -$2.73M ﹤0.01% 3713
2023
Q1 		$4.59M Buy
2,353,705
+192,349
+9% +$710K ﹤0.01% 3146
2022
Q4 		$8.3M Buy
2,161,356
+2,132,701
+7,443% +$8.53M ﹤0.01% 2743
2022
Q3 		$138K Buy
+28,655
New +$208K ﹤0.01% 5602

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ADCT Position: Q1 2026 in Review

Goldman Sachs increased its ADC Therapeutics (ADCT) stake by 0.74% in Q1 2026, buying an estimated $47.9K and bringing the position to 1,653,026 shares worth $6.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Goldman Sachs first reported a position in ADCT in Q3 2022 and has held it in 15 quarters since. The position peaked at $8.3M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Goldman Sachs held 1,653,026 shares of ADC Therapeutics worth $6.2M as of Q1 2026.
  • Goldman Sachs bought 12,154 ADC Therapeutics shares in Q1 2026, an estimated $47.9K.
  • ADC Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3485 holding.
  • Goldman Sachs first reported a position in ADC Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Goldman Sachs's ADC Therapeutics position peaked at $8.3M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.